Anje CAUWELS
9Patents
3h-index
10Co-inventors
46Inventor score
Filing activity: Jan 15, 2015 → Dec 17, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11236166B2 | CD8 binding agents | Emerging Cross-Sectional Technologies | 6 | Active |
| US11001631B2 | Clec9A binding agents | Emerging Cross-Sectional Technologies | 5 | Active |
| US10988538B2 | Bispecific signaling agents and uses thereof | Emerging Cross-Sectional Technologies | 4 | Active |
| US11248057B2 | CD20 binding single domain antibodies | Chemistry; Metallurgy | 2 | Active |
| US11753463B2 | Therapeutic targeting of non-cellular structures | Chemistry; Metallurgy | 0 | Active |
| US11896643B2 | Fibroblast binding agents and use thereof | Chemistry; Metallurgy | 0 | Active |
| US9919048B2 | Targeting of interleukin-1 and -18 signaling in treatment of septic shock | Chemistry; Metallurgy | 0 | Active |
| US12410225B2 | Modulation of dendritic cell lineages | Chemistry; Metallurgy | 0 | Active |
| US12364753B2 | CD8 binding agents | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.